Jump to content



Recommended Posts

Treatment credited with 92 percent success in early-stage NSCLC

RITA Medical Systems on June 8 announced that early results from an international multicenter prospective clinical trial show a 92 percent survival rate in stage I non-small cell lung cancer (NSCLC) patients treated with RITA radiofrequency ablation (RFA) as the sole anti-cancer treatment.

Riccardo Lencioni, M.D., professor of diagnostic and interventional radiology at the University of Pisa in Italy, presented the results at the American Society of Clinical Oncology annual meeting.

The trial focused on patients with primary NSCLC originating in the lungs that had not progressed to local lymph nodes. It included 14 patients with stage I biopsy-proven NSCLC lesions ranging in size from 1.0 to 3.0 cm. All patients were considered unfit for surgery and radiation therapy due to co-morbidity or reduced pulmonary function.

Researchers were able to successfully perform RITA RFA in a single treatment session in all of the patients. Two patients with local tumor progression required re-treatment. Cancer specific survival at one year in all patients was 92.3 percent, and overall survival at one year was 80.8 percent including death from causes other than tumor progression.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.